Stock listing

Syntara Limited

Selected listing: A3E4P8 · LS · EUR · DE

Syntara Limited (Lang & Schwarz: A3E4P8), Health Technology. Latest release Oct 6, 2026: Further significant results from SNT-4728 iRBD Phase 2 trial.

A3E4P8:LSEURDEUpdated October 2, 2026

Ticker: Lang & Schwarz: A3E4P8
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Lang & Schwarz
Currency: EUR

About Syntara Limited

The company operates in the resource sector, focusing on exploration and development activities. Syntara is committed to advancing its projects and enhancing shareholder value through strategic initiatives.

Latest news from Syntara Limited

Further significant results from SNT-4728 iRBD Phase 2 trial

October 6, 2026

Syntara expands SNT-9465 skin scarring study

September 30, 2026

Appendix 4E and Annual Report

August 27, 2026

Encouraging SNT-4728 Phase 2 iRBD results

July 5, 2026

Results of Share Purchase Plan

June 10, 2026

All Syntara Limited news →

Research Syntara Limited

Syntara Limited company profile

View the public company page for Syntara Limited on 6ix.

Syntara Limited news

Read company news and market updates connected to Syntara Limited.

Syntara Limited investor events

Find investor webinars, events, and replay context for Syntara Limited.